43E0 Stock Chart & Stats
€5.35
-€0.10(-0.59%)
At close: 4:00 PM EST
€5.35
-€0.10(-0.59%)
Day’s Range― - ―
52-Week Range€3.48 - €9.10
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€42.73M
Enterprise Value€54.64
Total Cash (Recent Filing)€8.83M
Total Debt (Recent Filing)€9.48M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 12, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding8,295,707
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)-22.29
Price to Sales (P/S)1.19
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.52Price Target Upside171.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)€36.72M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue ScalingSustained high gross margins (~81–87%) alongside multi-year revenue scaling demonstrate durable unit economics and pricing power. Strong gross-profit generation underpins the ability to invest in commercialization and R&D while improving operating leverage over the medium term.
Federal (VA/DoD) Channel TractionMeaningful VA adoption creates a defendable, repeatable channel with reimbursement-backed demand. Federal penetration, complemented by DoD research ties, can yield predictable, recurring revenue and higher retention versus consumer channels over multiple quarters to years.
R&D And Regulatory ProgressRegulatory recognition (Breakthrough Device) and active clinical programs expand potential indications beyond headaches. Progress in PTSD, TACSTIM DoD research, and a next‑gen platform support durable pipeline value and broaden addressable markets over a multi-year horizon.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows force reliance on external financing. Over months this increases dilution or refinancing risk, constraining the company’s ability to fund growth, inventory, and commercialization without access to capital markets.
Weakened Balance Sheet And Negative EquityTransition to negative equity and shrinking assets materially reduce financial flexibility. This structural weakening elevates refinancing and covenant risks, and limits capacity to absorb shocks or invest without dilutive financings over the medium term.
Concentration And Reimbursement DependenceRevenue concentration in specific channels (VA, select prescriptions) and reliance on payer coverage make growth sensitive to reimbursement decisions and execution. Variable product lines like TACSTIM increase revenue volatility and execution risk over quarters to years.
Electrocore News
43E0 FAQ
What was Electrocore Llc’s price range in the past 12 months?
Electrocore Llc lowest stock price was €3.48 and its highest was €9.10 in the past 12 months.
What is Electrocore Llc’s market cap?
Electrocore Llc’s market cap is €42.73M.
When is Electrocore Llc’s upcoming earnings report date?
Electrocore Llc’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Electrocore Llc’s earnings last quarter?
Electrocore Llc released its earnings results on May 06, 2026. The company reported -€0.517 earnings per share for the quarter, beating the consensus estimate of -€0.536 by €0.019.
Is Electrocore Llc overvalued?
According to Wall Street analysts Electrocore Llc’s price is currently Undervalued.
Does Electrocore Llc pay dividends?
Electrocore Llc does not currently pay dividends.
What is Electrocore Llc’s EPS estimate?
Electrocore Llc’s EPS estimate is -0.37.
How many shares outstanding does Electrocore Llc have?
Electrocore Llc has 8,295,707 shares outstanding.
What happened to Electrocore Llc’s price movement after its last earnings report?
Electrocore Llc reported an EPS of -€0.517 in its last earnings report, beating expectations of -€0.536. Following the earnings report the stock price went down -5.217%.
Which hedge fund is a major shareholder of Electrocore Llc?
Currently, no hedge funds are holding shares in DE:43E0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electrocore Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€14.52 (171.49% Upside)
€14.52 (171.49% Upside)
Insider Transactions
Sold Shares
Worth €492.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.48%
Trailing 12-Months
Company Description
Electrocore Llc
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
43E0 Stock 12 Month Forecast
Average Price Target
€14.52
▲(171.49% Upside)
Technical Analysis
Myomo
―
Modular Medical
―
NeuroOne Medical Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―